Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q15170
UPID:
TCAL1_HUMAN
Alternative names:
Nuclear phosphoprotein p21/SIIR; Transcription elongation factor S-II protein-like 1
Alternative UPACC:
Q15170; Q9UJQ9
Background:
Transcription elongation factor A protein-like 1, also known as Nuclear phosphoprotein p21/SIIR, plays a crucial role in transcriptional regulation. It modulates various viral and cellular promoters in a context-dependent manner, enhancing transcription from the FOS promoter while repressing Rous sarcoma virus (RSV) long terminal repeat (LTR) promoter activity. This protein does not bind DNA directly.
Therapeutic significance:
Linked to a neurodevelopmental disorder characterized by hypotonia, abnormal gait, and intellectual disability, understanding the role of Transcription elongation factor A protein-like 1 could open doors to potential therapeutic strategies.